Curcumin for Inflammaging Reduction

Inflammaging describes the chronic, low-grade, sterile inflammation that rises with age and correlates with cardiovascular disease, frailty, cognitive decline and mortality. It is a real and well-documented phenomenon, and also a marketing magnet.

Curcumin is a plausible candidate because it inhibits NF-kB, the transcription factor sitting at the centre of the inflammatory programme that inflammaging describes. Trials have reported reductions in CRP and IL-6 in various populations. The honest limitation is the endpoint. Lowering an inflammatory marker is not the same as slowing ageing or preventing the diseases those markers predict. No trial has shown curcumin to extend healthspan, reduce frailty incidence or lower age-related disease risk in humans, and marker-level results have repeatedly failed to translate elsewhere in medicine.

Inflammaging arises from several converging sources: accumulation of senescent cells secreting inflammatory mediators, mitochondrial dysfunction, impaired autophagy, gut barrier permeability and lifelong antigenic burden. NF-kB is the shared downstream node through which most of these produce cytokines.

Curcumin inhibits NF-kB activation and reduces TNF-alpha, IL-1beta and IL-6 expression, and laboratory work has also described senolytic-like and autophagy-promoting effects, though these remain preclinical. A plausible additional route is intestinal. Because most oral curcumin stays in the gut, effects on barrier integrity and the microbiome could reduce translocation of bacterial products that drive systemic inflammation - a mechanism that does not require good absorption at all.

Doses in ageing and inflammation research resemble those used in other systemic indications.

There are currently no studies linked to this pairing in our library, so no study list is shown.

In the wider literature, meta-analyses of randomised trials report that curcumin lowers circulating CRP, IL-6 and TNF-alpha modestly, with larger effects in populations that start with elevated inflammation such as metabolic syndrome or arthritis. Healthy participants with normal baseline markers show much smaller changes. Direct evidence for inflammaging as such is absent. There are no long-duration trials in older adults with clinical ageing outcomes - frailty, disability, incident disease or mortality - and preclinical lifespan work in model organisms does not reliably translate. This is a mechanistically reasoned use, not a demonstrated one.

Curcumin is generally well tolerated, with gastrointestinal upset the most common complaint. Long-term daily use in older adults deserves a little more caution than short courses.

Rare hepatotoxicity has been reported, more often with high-dose and enhanced-bioavailability products, so periodic liver function testing is sensible during prolonged use. Antiplatelet activity matters before surgery, and iron chelation is relevant in older adults with anaemia.

Interaction risk is the dominant practical consideration in the age group most interested in this outcome.

No studies are currently linked to this pairing, so no reference list is available. This section will populate as evidence is added to the library.